Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.) on October 28, 2008. The report details corporate governance amendments effective as of the filing date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal and governance changes rather than financial performance.
Material Changes
The Board of Directors amended and restated the Company's bylaws to implement the following changes:
- Reflect the name change from Sonus Pharmaceuticals, Inc. to OncoGenex Pharmaceuticals, Inc.
- Prohibit shareholder action via written consent without a meeting.
- Restrict changes to the number of directors to a vote of the directors only, removing the option for a shareholder vote.
- Make various technical and typographical corrections.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to disclose the amendment of bylaws and the corporate name change.
Key Facts for Investor Verification
- Confirm the legal name change from Sonus Pharmaceuticals, Inc. to OncoGenex Pharmaceuticals, Inc.
- Verify the new restriction requiring a director vote (rather than a shareholder vote) to change the number of directors.
- Note the elimination of written consent as a method for shareholder action without a meeting.